Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Allergan taps Pfizer vet Hugh-Jones as CMO
Tuesday, August 14, 2018
As Allergan enters a key phase for its late-stage products, it’s bringing in a veteran exec for backup.
BMS to lay off 149 as Wallingford site nears closure
Tuesday, July 17, 2018
BMS already cut 107 positions at the facility earlier this year, and plans to close it by year's end.
FiercePharmaAsia—Sanofi, Takeda, I-Mab and more
Friday, July 6, 2018
Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.
Merck has hardened its defenses against cyberattacks
Thursday, June 28, 2018
Merck says if it were hit again by cyberattack like last year's NotPetya, it would be able to recover more quickly
Sarepta CEO Ingram nabs $57M in 2017 pay
Monday, May 7, 2018
Sarepta CEO Douglas Ingram may have netted biopharma's biggest 2017 compensation package after six months on the job.
Relax, Celgene investors. The situation isn't all that bad: analyst
Thursday, March 29, 2018
Celgene’s stock has taken a beating thanks to a string of bad news. But the situation isn’t as dire as its share price suggests, one analyst insists.
FiercePharmaAsia—Takeda, China’s supply issues, Merck KGaA
Friday, February 23, 2018
Takeda made two R&D deals, China's crackdown on pollution causes pharma supply issues, Merck KGaA plans production expansions in Asia.
FiercePharmaAsia—Takeda, Shanghai Pharma, WuXi NextCODE
Friday, January 26, 2018
Takeda-Zinfandel dropped an Alzheimer’s study; Shanghai Pharma will open an R&D site in the U.S.; NextCODE CEO talked about company plans.
Sanofi, Regeneron sock $1B-plus into new meds, Dupixent included
Monday, January 8, 2018
With PCSK9 cholesterol drug Praluent ramping up more slowly than expected, Sanofi and Regeneron plan a new investment in blockbuster hopeful Dupixent.